Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Baas

Showing results (151-160 of 159) with videos related to

Pageof 16
Sort By:
You have reached the last page of results.This site can display upto 159 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2019
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breathR de Vries, M Muller, V van der Noort, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†G R Blumenschein, E F Smit, D Planchard, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2002
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001J R Fischer, P Baas, H D Becker, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 18, 2015
Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: Results of the randomized "CEAwatch" trialC J Verberne, Z Zhan, E van den Heuvel, et al.
Neuroscience and Biobehavioral Reviews|March 7, 2017
Don't fear 'fear conditioning': Methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fearTina B Lonsdorf, Mareike M Menz, Marta Andreatta, et al.
Lung Cancer (Amsterdam, Netherlands)|November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohortJ W T van der Wel, M Jebbink, D van den Broek, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialR S Herbst, P Baas, J L Perez-Gracia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
Pageof 16

Showing results (151-160 of 159) with videos related to

Sort By:
Pageof 16
You have reached the last page of results.This site can display upto 159 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 19, 2019
Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breathR de Vries, M Muller, V van der Noort, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2015
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†G R Blumenschein, E F Smit, D Planchard, et al.
Lung Cancer (Amsterdam, Netherlands)|April 17, 2002
Report from the first meeting of the 'European Network on Translational Research in Lung Cancer Amsterdam-Barcelona-Bialystok-Heidelberg'. Thoraxklinik Heidelberg, Germany, July 25, 2001J R Fischer, P Baas, H D Becker, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|July 18, 2015
Intensified follow-up in colorectal cancer patients using frequent Carcino-Embryonic Antigen (CEA) measurements and CEA-triggered imaging: Results of the randomized "CEAwatch" trialC J Verberne, Z Zhan, E van den Heuvel, et al.
Neuroscience and Biobehavioral Reviews|March 7, 2017
Don't fear 'fear conditioning': Methodological considerations for the design and analysis of studies on human fear acquisition, extinction, and return of fearTina B Lonsdorf, Mareike M Menz, Marta Andreatta, et al.
Lung Cancer (Amsterdam, Netherlands)|November 18, 2024
Combined analysis of circulating tumor DNA and tumor tissue to overcome osimertinib resistance (OSIRIS); the second line osimertinib cohortJ W T van der Wel, M Jebbink, D van den Broek, et al.
ESMO Open|February 5, 2026
Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLCN Girard, J Bar, P Baas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 19, 2019
Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trialR S Herbst, P Baas, J L Perez-Gracia, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 30, 2017
Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape ProjectK M Kerr, U Dafni, K Schulze, et al.
Pageof 16